Abstract:

OBJECTIVE: To evaluate the application of anti-tumor sustained-release reagent in gastrointestinal tumors, and to find a reasonable treatment.
METHODS: Using “esophageal cancer, gastric cancer, liver cancer, colon cancer, implantation of chemotherapy , sustained- release implants, chemical drugs” as the Chinese keywords and “esophageal cancer, gastric cancer, liver cancer, colon cancer, implantation of chemotherapy , sustained release implants, chemicals” as the English keywords, a computer search was performed among articles published between January 1993 and October 2009. Articles related with the biological materials and tissue engineering blood vessels were included; repeated study or Meta analysis articles were excluded.
RESULTS: The implanted sustained-release implants of chemotherapy (i.e. chemotherapeutics) may restrict the drug dissolution and diffusion rate through different carriers and preparation techniques, slowly and continuously release drugs, those drugs at a relatively stable maximal concentration only works in local part. In the digestive tract tumor or residual tumor and possible tiny tumor metastases locus, we may implant sustained-release chemotherapy reagents, thus improving local drug dose and action time, while reducing or avoiding side effects caused by the common chemotherapy, providing a new route of administration for chemical treatment of tumors; intratumoral injection of chemotherapy sustained-release reagent can reduce pain and bring new hope for tumor patients at advanced stage who are absent for surgery, radiotherapy or common chemotherapy.
CONCLUSION: The anti-tumor sustained-release reagent can be used as an ideal sustained-release implant in digestive tract cancer.